The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase (Ph) 1/2 study of TSR-011, a potent inhibitor of ALK and TRK, including crizotinib-resistant ALK mutations.
Glen J. Weiss
No relevant relationships to disclose
Jasgit C. Sachdev
No relevant relationships to disclose
Jeffrey R. Infante
No relevant relationships to disclose
Monica M. Mita
No relevant relationships to disclose
Ronald B. Natale
Research Funding - Tesaro
Hendrik-Tobias Arkenau
No relevant relationships to disclose
Keith Wilcoxen
Employment or Leadership Position - Tesaro
Stock Ownership - Tesaro
Vikram Kansra
Employment or Leadership Position - Tesaro
Stock Ownership - Tesaro
Haley Laken
Employment or Leadership Position - Tesaro
Stock Ownership - Tesaro
Lorraine Hughes
Employment or Leadership Position - Tesaro
Stock Ownership - Tesaro
David G. Brooks
Employment or Leadership Position - Tesaro
Stock Ownership - Tesaro
Robert E. Martell
Employment or Leadership Position - Tesaro
Stock Ownership - Tesaro
Stephen Patrick Anthony
No relevant relationships to disclose